Location · Newton, MA
Clinical trials in Newton, MA
12 recruiting studies have a site in Newton, and 1 of them accept healthy volunteers.
12 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Sanofi
- Location
- Newton, MA + 9 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Newton, MA + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Newton, MA + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb
- Location
- Newton, MA + 10 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb
- Location
- Newton, MA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Newton, MA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Newton, MA + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Newton, MA + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Eli Lilly and Company
- Location
- Newton, MA + 41 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
- Location
- Newton, MA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Takeda
- Location
- Newton, MA + 18 other US sites
- Eligibility basics
- Ages 16–70
- RecruitingHealthy volunteersPhase 4
BoTox Into the Sternocleidomastoid Muscles (SCM)
Boston Medical Center
- Location
- Newton, MA
- Eligibility basics
- Ages 18–65